LCM
REGN icon

Legato Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Legato Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Sell
3,664
-2,340
-39% -$1.59M 0.19% 167
2026
Q1 		$4.64M Sell
6,004
-2,799
-32% -$2.14M 0.42% 37
2025
Q4 		$6.79M Sell
8,803
-1,400
-14% -$951K 0.58% 20
2025
Q3 		$5.74M Buy
10,203
+419
+4% +$237K 0.62% 24
2025
Q2 		$5.14M Hold
9,784
– – 0.61% 27
2025
Q1 		$6.21M Buy
9,784
+5,277
+117% +$3.63M 0.84% 9
2024
Q4 		$3.21M Buy
4,507
+411
+10% +$345K 0.42% 35
2024
Q3 		$4.31M Sell
4,096
-298
-7% -$332K 0.53% 23
2024
Q2 		$4.62M Sell
4,394
-1,301
-23% -$1.26M 0.62% 19
2024
Q1 		$5.48M Buy
5,695
+200
+4% +$190K 0.66% 18
2023
Q4 		$4.83M Hold
5,495
– – 0.63% 25
2023
Q3 		$4.52M Hold
5,495
– – 0.66% 22
2023
Q2 		$3.95M Hold
5,495
– – 0.53% 32
2023
Q1 		$4.52M Hold
5,495
– – 0.82% 10
2022
Q4 		$3.96M Buy
+5,495
New +$4.05M 0.76% 11
2021
Q3 		– Sell
-2,793
Closed -$1.56M – 289
2021
Q2 		$1.56M Buy
+2,793
New +$1.41M 0.22% 108

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Legato Capital Management's REGN Position: Q2 2026 in Review

Legato Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 39% in Q2 2026, selling an estimated $1.59M and leaving 3,664 shares worth $2.28M. The position accounts for 0.19% of the portfolio, ranked #167.

Legato Capital Management first reported a position in REGN in Q2 2021 and has held it in 16 quarters since. The position peaked at $6.79M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Legato Capital Management held 3,664 shares of Regeneron Pharmaceuticals worth $2.28M as of Q2 2026.
  • Legato Capital Management sold 2,340 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.59M.
  • Regeneron Pharmaceuticals made up 0.19% of Legato Capital Management's portfolio in Q2 2026, its #167 holding.
  • Legato Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 16 quarters since.
  • Legato Capital Management's Regeneron Pharmaceuticals position peaked at $6.79M in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.